Hepatitis C and iron

Keio Journal of Medicine

Volumn 48, Issue 3, 1999, Pages 124-131

  Olynyk, John K ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Ferritin; Hepatitis C virus; Interferon; Iron metabolism

Indexed keywords

ALPHA INTERFERON; FERRITIN; IRON;

CELLULAR DISTRIBUTION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON METABOLISM; IRON OVERLOAD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MISSENSE MUTATION; PATHOPHYSIOLOGY; REVIEW; VIRUS HEPATITIS;

EID: 0032882749     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.48.124     Document Type: Review

References (103)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al.: Treatment of chronic hepatitis C with recombinant interferon α. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-1506
2. Saracco G, Rizzetto M: The long-term efficacy of interferon α in chronic hepatitis C patients: a critical review. J Gastroenterol Hepatol 1995; 10: 668-673
3. Smith BC, Strasser SI, Desmond PV: Current perspectives in hepatitis C. Aust N Z J Med 1995; 25: 350-357
4. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, et al.: Comparison of 1 or 3 MU of interferon α-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502
5. Lin R, Schoeman MN, Craig PI, Bilous M, Grierson J, McDonald JA, Batey RG, Farrell GC: Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust N Z J Med 1991; 21: 387-392
6. Perez R, Pravia R, Linares A, Rodriguez M, Lombrana JL, Suarez A, Riestra S, Navascues CA, Rodrigo L: Response related factors in recombinant interferon α-2b treatment of chronic hepatitis C. Gut 1993; 34 (2 Suppl): 139-140
7. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-1504
8. Tsubota A, Chayama K, Arase Y, Koida I, Saitoh S, Ikeda K, Iwasaki S, Matsumoto T, Kobayashi M, Kumada H: Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 1993; 8: 535-539
9. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, Kamada T: Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977-982
10. Pagliaro L, Craxi A, Cammaa C, Tine F, Di Marco V, Lo Iacono O, Almasio P: Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-828
11. Davis GL: Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3
12. Britton RS, Ramm GA, Olynyk J, Singh R, O'Neill R, Bacon BR: Pathophysiology of iron toxicity. Adv Exp Med Biol 1994; 356: 239-253
13. Worwood M: Serum ferritin. Clin Sci 1986; 70: 215-220
14. Powell LW, Jazwinska E, Halliday JW: Primary iron overload. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds, Iron Metabolism in Health and Disease, London, W B Saunders, 1994; 227-270
15. Olynyk JK, O'Neill R, Britton RS, Bacon BR: Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications. Gastroenterology 1994; 106: 674-677
16. Torrance JD, Bothwell TH: Tissue iron stores. In: Cook JD, ed, Iron, New York, Churchill Livingstone, 1980: 90-115
17. Olynyk J, Hall P, Sallie R, Reed W, Shilkin K, Mackinnon M: Computerized measurement of iron in liver biopsies: a comparison with biochemical iron measurement. Hepatology 1990; 12: 26-30
18. Searle JW, Kerr JFR, Halliday JW, Powell LW: Iron storage disease. In: MacSween RNM, Anthony PP, Scheuer PJ, eds, Pathology of the Liver. 2nd Ed, Edinburgh, Churchill Livingstone, 1987; 181-201
19. Prieto J, Barry M, Sherlock S: Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology 1975; 68: 525-533
20. Sutnick AI, Blumberg BS, Lustbader ED: Elevated serum iron levels and persistent Australia antigen (HBsAG). Ann Intern Med 1974; 81: 855-856
21. Lustbader ED, Hann HW, Blumberg BS: Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220: 423-425
22. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR: Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-2113
23. Riggio O, Montagnese F, Fiore P, Folino S, Giambartolomei S, Gandin C, Merli M, Quinti I, Violante N, Caroli S, Senofonte O, Capocaccia L: Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol 1997; 92: 1298-1301
24. Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M, Halpern Z, Weiss H, Gilat T: Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994; 39: 2656-2659
25. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS: Response to interferon α therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-415
26. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR: Hepatic iron concentration as a predictor of response to interferon a therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-1109
27. Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y: Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997; 41: 115-120
28. Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, Cesana B, Lunghi G, Piperno A, Valsecchi C, Fiorelli G: Liver iron influences the response to interferon α therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997; 9: 497-503
29. Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A, Opolon P, Holstege A, Poynard T, Bedossa P: In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997; 50: 401-406
30. Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, Noguchi O, Miyake S, Nouchi T, Fujisawa K, Marumo F, Sato C: Hepatic iron contents and response to interferon-α in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci 1996; 41: 989-994
31. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M: Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996; 91: 1367-1373
32. Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL: A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 1995; 8: 232-238
33. Barton AL, Banner BF, Cable EE, Bonkovsky HL: Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995; 103: 419-424
34. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N: Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-988
35. Piperno A, D'Alba R, Fargion S, Roffi L, Sampietro M, Parma S, Arosio V, Fare M, Fiorelli G: Liver iron concentration in chronic viral hepatitis: a study of 98 patients. Eur J Gastroenterol Hepatol 1995; 7: 1203-1208
36. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, Malizia R, Maggio A, Fabiano C, Barbaria F, Craxi A: Long-term efficacy of α-interferon in β-thalassemics with chronic hepatitis C. Blood 1997; 90: 2207-2212
37. Hayashi H, Takikawa T, Nishimura N, Yano M: Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 1995; 22: 268-271
38. Bacon BR, Rebholz AE, Fried M, Di Bisceglie AM: Beneficial effect of iron reduction therapy in patients with chronic hepatitis C, who failed to respond to interferon-α. Hepatology 1993; 18: 150A
39. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, Nicoli C, Corbetta N, Pozzi M, Arosio V, Boari G, Fiorelli G: Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16: 248-254
40. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, Faa G, Diana G, Dessi C, et al.: Effect of iron overload on the response to recombinant interferon-α treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994; 125: 123-128
41. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE: Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996; 25: 633-638
42. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A: Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol 1995; 26: 1080-1085
43. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, Phan C, Goad K, Redeker AG: A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C. J Hepatol 1998; 28: 369-374
44. Kaserer K, Fiedler R, Steindl P, Muller CH, Wrba F, Ferenci P: Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998; 32: 454-461
45. D'Alba R, Sampietro M, Fargion S, Roffi L, Parma S, Pozzi M, Nicoli C, Corbetta N, Arosio V, Piperno A: Iron stores and virus genotypes in chronic hepatitis C: relation with α-interferon response. Hepatology 1995; 22: 180A
46. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH: Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116: 193-207
47. Stuart KA, Busfield F, Jazwinska EC, Gibson P, Butterworth LA, Cooksley WG, Powell LW, Crawford DH: The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors of porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28: 404-409
48. Barrett S, Callagy G, Ryan E, O'Keane JC, Mathuna PM, Crowe J: The C282Y mutation is not a significant cofactor for more severe liver disease in a cohort of Irish hepatitis C patients. Gastroenterology 1988; 114: A1209
49. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK: HFE genotype in patients with hemochromatosis and other liver disease. Ann Int Med 1999; 130: 953-962
50. Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF: Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695-1699
51. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, LeClair P, Mercurio MG, Lambrecht RW: Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998: 27; 1661-1669
52. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH: Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321-323
53. Stal P, Hultcrantz R: Iron increases ethanol toxicity in rat liver. J Hepatol 1993; 17: 108-115
54. Olynyk J, Hall P, Reed W, Williams P, Kerr R, Mackinnon M: A long-term study of the interaction between iron and alcohol in an animal model of iron overload. J Hepatol 1995; 22: 671-676
55. Mackinnon M, Clayton C, Plummer J, Ahern M, Cmielewski P, Ilsley A, Hall P: Iron overload facilitates hepatic fibrosis in the rat alcohol/low-dose carbon tetrachloride model. Hepatology 1995; 21: 1083-1088
56. Higueras V, Raya A, Rodrigo JM, Serra MA, Roma J, Romero FJ: Interferon decreases serum lipid peroxidation products of hepatitis C patients. Free Radic Biol Med 1994; 16: 131-133
57. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R: Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-456
58. Kikuyama M, Kobayashi Y, Kawasaki T, Yoshimi T: Hepatic lipid peroxidation in chronic hepatitis C. Hepatology 1995; 22: 276A
59. Maher JJ, Zia S, Tzagarakis C: Acetaldehyde-induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: studies with rat lipocytes and fibroblasts. Alcohol Clin Exp Res 1994; 18: 403-409
60. Maher JJ, Tzagarakis C, Gimenez A: Malondialdehyde stimulates collagen production by hepatic lipocytes only upon activation in primary culture. Alcohol Alcohol 1994; 29: 605-610
61. 1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 1997; 11: 851-857
62. 1 gene expression in the rat liver. FEBS Lett 1992; 308: 267-270
63. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D: Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26: 485-490
64. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53
65. Kew MC: Hepatic tumors and cysts. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds, Sleisenger and Fordtran's Gastrointestinal and Liver Diseases: Pathophysiology/diagnosis/ management. 6th Ed, Philadelphia, W B Saunders Co, 1998; 1364-1387
66. Sell S, Dunsford HA: Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 1989; 134: 1347-1363
67. Lemire JM, Shiojiri N, Fausto N: Oval cell proliferation and the origin of small hepatocytes in liver injury induced by D-galactosamine. Am J Pathol 1991; 139: 535-552
68. Evarts RP, Nagy P, Marsden E, Thorgeirsson SS: A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis 1987; 8: 1737-1740
69. Hixson DC, Fowler LC: Development and phenotypic heterogeneity of intrahepatic biliary epithelial cells. In: Sirica AE, Longnecker DS, eds, Biliary and Pancreatic Ductal Epithelia: Pathobiology and Pathophysiology, New York, Marcel Dekker, 1997; 1-40
70. Ray MB, Mendenhall CL, French SW, Gartside PS: Bile duct changes in alcoholic liver disease. The Veterans Administration Cooperative Study Group. Liver 1993; 13: 36-45
71. Hsia CC, Evarts RP, Nakatsukasa H, Marsden ER, Thorgeirsson SS: Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology 1992; 16: 1327-1333
72. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK: Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999; 154: 537-541
73. Britton RS, Edling JE, Grisham MB, Bacon BR: Hepatic DNA damage in rats with chronic dietary iron overload. Hepatology 1991; 21: 4
74. Nordenson I, Ritter B, Beckman A, Beckman L: Idiopathic hemochromatosis and chromosomal damage. Hum Hered 1992; 42: 143-145
75. Gonzalez-Peralta RP, Davis GL, Lau JY: Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994; 21: 255-259
76. Mondelli MU, Cerino A, Bellotti V, de Koning A: Immunobiology and pathogenesis of hepatitis C virus infection. Res Virol 1993; 144: 269-274
77. Cerny A, Chisari FV: Immunological aspects of HCV infection. Intervirology 1994; 37: 119-125
78. Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31: 2679-2682
79. Horvath J, Raffanti SP: Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994; 18: 339-347
80. Senba M, Nakamura T, Itakura H: Statistical analysis of relationship between iron accumulation and hepatitis B surface antigen. Am J Clin Pathol 1985; 84: 340-342
81. Bullen JJ, Spalding PB, Ward CG, Gutteridge JM: Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 1991; 151: 1606-1609
82. Good MF, Powell LW, Halliday JW: Iron status and cellular immune competence. Blood Rev 1988; 2: 43-49
83. Good MF, Chapman DE, Powell LW, Halliday JW: The effect of experimental iron-overload on splenic T cell function: analysis using cloning techniques. Clin Exp Immunol 1987; 68: 375-383
84. Gascon P, Zoumbos NC, Young NS: Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med 1984; 100: 173-177
85. Kaplan J, Sarnaik S, Gitlin J, Lusher J: Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 1984; 64: 308-310
86. Akbar AN, Fitzgerald-Bocarsly PA, de Sousa M, Giardina PJ, Hilgartner MW, Grady RW: Decreased natural killer activity in thalassemia major: a possible consequence of iron overload. J Immunol 1986; 136: 1635-1640
87. Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G: Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol 1979; 42: 345-353
88. Harada T, Baba M, Torii I, Morikawa S: Ferritin selectively suppresses delayed-type hypersensitivity responses at induction or effector phase. Cell Immunol 1987; 109: 75-88
89. Pattanapanyasat K, Hoy TG, Jacobs A: The response of intracellular and surface ferritin after T-cell stimulation in vitro. Clin Sci 1987; 73: 605-611
90. Konijn AM, Meyron-Holtz EG, Levy R, Ben-Bassat H, Matzner Y: Specific binding of placental acidic isoferritin to cells of the T-cell line HD-MAR. FEBS Lett 1990; 263: 229-232
91. Moss D, Powell LW, Arosio P, Halliday JW: Characterization of the ferritin receptors of human T lymphoid (MOLT-4) cells. J Lab Clin Med 1992; 119: 273-279
92. Chelbi-Alix MK, Thang MN: Multiple molecular forms of interferon display different specific activities in the induction of the antiviral state and 2′5′ oligoadenylate synthetase. Biochem Biophys Res Commun 1986; 141: 1042-1050
93. Bacon BR, Fried MW, DiBisceglie AM: A 39-year-old man with chronic hepatitis, elevated serum ferritin values, and a family history of hemochromatosis. Semin Liver Dis 1993; 13: 101-105
94. Ward RJ, O'Connell MJ, Dickson DP, Reid NM, Wade VJ, Mann S, Bomford A, Peters TJ: Biochemical studies of the iron cores and polypeptide shells of haemosiderin isolated from patients with primary or secondary haemochromatosis. Biochim Biophys Acta 1989; 993: 131-133
95. van Asbeck BS, Verbrugh HA, van Oost BA, Marx JJ, Imhof HW, Verhoef J: Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J (Clin Res Ed) 1982; 284: 542-544
96. van Asbeck BS, Marx JJ, Struyvenberg A, Verhoef J: Functional defects in phagocytic cells from patients with iron overload. J Infect 1984; 8: 232-240
97. Ballart IJ, Estevez ME, Sen L, Diez RA, Giuntoli J, de Miani SA, Penalver J: Progressive dysfunction of monocytes associated with iron overload and age in patients with thalassemia major. Blood 1986; 67: 105-109
98. Olynyk J, Clarke SL: Functional heterogeneity of Kupffer cells in iron overload. Hepatology 1998; 28: 441A
99. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Fagiuoli S, Wright HI, Gasbarrini A, Caraceni P: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 1996; 43: 1557-1561
100. Bayraktar Y, Koseoglu T, Kayhan B, Uzunalimoglu B, Gurakar A, Van Thiel DH: The use of desferrioxamine infusions to enhance the response rate to interferon α (IFN) treatment of chronic viral hepatitis. Gastroenterology 1995; 108 (4 Suppl): A1031
101. Kugelmas M, Lieberman BY, Carey WD: Deironization in chronic hepatitis C patients previously non-responsive to interferon improves transaminases but not viral activity. Gastroenterology 1995; 108 (4 Suppl): A1104
102. Yano M, Kakumu S, Hayashi H, Takikawa T, Nishimura N: Phlebotomy followed by α-interferon therapy in patients with chronic hepatitis C, Hepatology 1995; 22: 119A
103. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL: Effect of iron depletion on long-term response to interferon-α in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997; 92: 1831-1834